tiprankstipranks
Trending News
More News >
Cyclerion Therapeutics,Inc. (CYCN)
NASDAQ:CYCN
US Market
Advertisement

Cyclerion Therapeutics (CYCN) AI Stock Analysis

Compare
242 Followers

Top Page

CYCN

Cyclerion Therapeutics

(NASDAQ:CYCN)

Rating:47Neutral
Price Target:
Cyclerion Therapeutics' overall stock score is primarily influenced by its financial difficulties, including consistent net losses and negative cash flows, despite having a solid equity position and no debt. The technical analysis provides a slightly more optimistic view with some bullish momentum, but the valuation remains unattractive due to ongoing financial challenges. The lack of earnings call or corporate events data means these factors did not affect the score.

Cyclerion Therapeutics (CYCN) vs. SPDR S&P 500 ETF (SPY)

Cyclerion Therapeutics Business Overview & Revenue Model

Company DescriptionCyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
How the Company Makes MoneyCyclerion Therapeutics makes money through the development and commercialization of its pharmaceutical products. As a clinical-stage company, its revenue streams can include research and development collaborations, licensing agreements, and potential milestone payments from partnerships. The company may also receive funding from grants or partnerships that support its research initiatives. Cyclerion’s financial performance is closely tied to the progress and success of its drug candidates in clinical trials, regulatory approvals, and eventual market entry. However, being in the clinical stage, the company might not have substantial revenue from product sales until its therapies receive regulatory approval and are commercially launched.

Cyclerion Therapeutics Financial Statement Overview

Summary
Cyclerion Therapeutics faces significant financial challenges with persistent net losses and negative cash flows, despite a strong equity position and no debt. Revenue growth has been inconsistent, and while the company maintains a high gross profit margin in revenue-generating years, operational and financial sustainability remains a concern. Continued focus on improving operational efficiency and cash flow generation is crucial for enhancing long-term financial health.
Income Statement
45
Neutral
Cyclerion Therapeutics has shown volatility in revenue generation with a decline in revenue from 2019 to 2024. Although there was a revenue increase from 2023 to 2024, overall growth remains inconsistent. The gross profit margin has remained 100% in years with revenue, but the company has consistently posted negative net income and EBIT, indicating ongoing challenges in managing operating expenses and achieving profitability. The net profit margin has been negative, which underscores persistent losses.
Balance Sheet
50
Neutral
Cyclerion's balance sheet reflects a strong equity position with zero debt in recent years, indicating potential stability in capital structure. However, the return on equity is negative due to consistent net losses, which is a concern for long-term sustainability. The equity ratio is relatively high due to low liabilities, suggesting reliance on equity financing but points to a lack of leverage for growth.
Cash Flow
35
Negative
The company is experiencing negative free cash flow, indicating challenges in generating cash from operations. The operating cash flow to net income ratio is negative due to significant cash outflows, and free cash flow has not shown growth, reflecting ongoing difficulties in achieving cash flow stability. This could impede future investment and operational flexibility.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.00M0.00297.00K3.32M2.30M
Gross Profit2.00M0.00232.00K2.85M2.30M
EBITDA-3.63M-12.59M-18.18M-55.20M-81.27M
Net Income-3.06M-21.02M-43.78M-51.66M-72.67M
Balance Sheet
Total Assets9.57M13.37M18.08M59.33M115.38M
Cash, Cash Equivalents and Short-Term Investments3.23M7.57M13.38M53.96M54.40M
Total Debt0.000.000.000.0045.73M
Total Liabilities725.00K2.09M7.63M11.09M55.88M
Stockholders Equity8.85M11.29M10.45M48.25M59.49M
Cash Flow
Free Cash Flow-4.33M-21.25M-40.61M-36.52M-74.01M
Operating Cash Flow-4.33M-21.25M-40.61M-36.52M-72.49M
Investing Cash Flow0.0010.40M0.001.46M18.00K
Financing Cash Flow0.005.02M29.00K30.79M28.09M

Cyclerion Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.02
Price Trends
50DMA
3.11
Negative
100DMA
2.95
Positive
200DMA
2.95
Positive
Market Momentum
MACD
0.01
Positive
RSI
46.17
Neutral
STOCH
29.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYCN, the sentiment is Negative. The current price of 3.02 is below the 20-day moving average (MA) of 3.20, below the 50-day MA of 3.11, and above the 200-day MA of 2.95, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 46.17 is Neutral, neither overbought nor oversold. The STOCH value of 29.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYCN.

Cyclerion Therapeutics Risk Analysis

Cyclerion Therapeutics disclosed 57 risk factors in its most recent earnings report. Cyclerion Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cyclerion Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
48
Neutral
$3.76M-205.75%2552.29%60.70%
47
Neutral
$9.63M-31.48%86.52%
46
Neutral
$16.48M-362.79%32.45%39.31%
46
Neutral
$10.67M-9999.00%-63.20%15.71%
40
Underperform
$10.68M-59.80%157.63%40.52%
34
Underperform
$8.37M-126.03%-100.00%-27.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CYCN
Cyclerion Therapeutics
3.02
-0.10
-3.21%
CARM
Carisma Therapeutics
0.39
-0.79
-66.95%
APRE
Aprea Therapeutics
1.93
-2.03
-51.26%
EVAX
Evaxion Biotech
2.71
-12.23
-81.86%
HCWB
HCW Biologics
4.26
-19.74
-82.25%
TSBX
Turnstone Biologics Corp.
0.36
-2.19
-85.88%

Cyclerion Therapeutics Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Cyclerion Therapeutics Secures Funding and Expands CNS Focus
Positive
Dec 17, 2024

Cyclerion Therapeutics has renegotiated its praliciguat license agreement with Akebia, securing $1.75 million in upfront and near-term payments while reducing operating expenses to focus on building its CNS pipeline. Additionally, Cyclerion entered into a license option agreement for olinciguat with CVCO Therapeutics, marking significant steps in monetizing its legacy assets and positioning itself for future growth by acquiring new CNS assets.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 20, 2025